Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| HCC1500 | THZ531 | 0.0001 | 0.9545 | -0.15048 |
| HCC1500 | THZ531 | 0.01 | -0.2739 | -0.14988 |
| HCC1500 | Ulixertinib | 0.1 | -0.2138 | -0.14975 |
| HCC1500 | BMS-265246 | 0.1 | 0.6640 | -0.14939 |
| HCC1500 | AZD6738 | 0.00316227766017 | 1.2436 | -0.14938 |
| HCC1500 | SHP099 | 0.00316227766017 | 0.8781 | -0.14783 |
| HCC1500 | GSK2334470 | 0.0316227766017 | 0.2312 | -0.14781 |
| HCC1500 | LY3023414 | 0.01 | -0.9698 | -0.14721 |
| HCC1500 | RO-3306 | 3.16227766017 | -0.4377 | -0.14697 |
| HCC1500 | Ribociclib | 10.0 | 1.2001 | -0.14639 |
| HCC1500 | AZD5363 | 0.0316227766017 | 0.1550 | -0.14632 |
| HCC1500 | Ulixertinib | 0.001 | 0.7505 | -0.14619 |
| HCC1500 | Ulixertinib | 0.01 | 0.3396 | -0.14614 |
| HCC1500 | GSK2334470 | 1.0 | -0.6510 | -0.14530 |
| HCC1500 | BMS-265246 | 0.0316227766017 | -0.0603 | -0.14523 |
| HCC1500 | RO-3306 | 0.1 | 0.4114 | -0.14377 |
| HCC1500 | SHP099 | 0.1 | 0.2576 | -0.14375 |
| HCC1500 | GSK2334470 | 0.1 | -0.2314 | -0.14240 |
| HCC1500 | THZ1 | 0.000316227766017 | 0.8970 | -0.14206 |
| HCC1500 | Senexin B | 3.16227766017 | -0.8412 | -0.14156 |
| HCC1500 | Alvocidib | 0.000316227766017 | 0.3396 | -0.14076 |
| HCC1500 | THZ531 | 0.0316227766017 | 0.7329 | -0.13990 |
| HCC1500 | Ulixertinib | 0.031622777 | 0.1305 | -0.13940 |
| HCC1500 | RO-3306 | 0.1 | 0.2444 | -0.13810 |
| HCC1500 | BMS-265246 | 0.01 | -0.3143 | -0.13677 |